Frankenfield Christopher's Insider Trades & SAST Disclosures
Frankenfield Christopher's most recent trade in Xilio Therapeutics Inc was a trade of 251,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Frankenfield Christopher.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 251,000 | 251,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 19,375 | 19,375 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 19,375 | 58,125 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 01 Jan 2025 | 6,954 | 12,421 | - | 1.0 | 6,841 | Common stock |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2024 | 52,000 | 52,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Christopher Frankenfield | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 208,000 | 208,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Frankenfield Christopher | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 77,500 | 77,500 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Christopher Frankenfield | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges